Clinical Trials Logo

Glaucoma clinical trials

View clinical trials related to Glaucoma.

Filter by:

NCT ID: NCT00961649 Terminated - Ocular Hypertension Clinical Trials

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to: - its individual components (Brinz and Brim), and - the concomitant administration of Brinz and Brim (Brinz+Brim).

NCT ID: NCT00901108 Terminated - Open Angle Glaucoma Clinical Trials

Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma

Start date: November 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of Trabectome versus Trabeculectomy with adjunctive Mitomycin C, combined with cataract surgery, in patients with open angle glaucoma.

NCT ID: NCT00811694 Terminated - Glaucoma Clinical Trials

Neurovascular Coupling in Patients With Open Angle Glaucoma

Start date: October 2006
Phase: N/A
Study type: Observational

A variety of studies demonstrate that ocular blood flow is altered in glaucoma. Various animal and human studies have shown an increase in retinal and optic nerve head blood flow in response to diffuse luminance flicker. Based on studies with ERG, this effect has been attributed to augmented activity in the retinal ganglion cells and associated axons indicating a coupling mechanism between neuronal activity and retinal blood flow. Whereas a variety of studies have confirmed these effects, the knowledge about this coupling in the retina of patients with glaucoma is sparse. Recently the investigators could show that flicker induced vasodilatation is blunted in patients with open angle glaucoma. However, the investigators results are limited by the fact that only data about retinal vessel diameters, not blood flow per se, are available. The further development of the investigators current flicker stimulation technique now allows us to determine blood flow velocity during flicker stimulation. Thus, in the current study, the investigators set out to determine whether this blood flow response is impaired in patients with glaucoma as compared to those in healthy volunteers and whether this is related to altered neural activity. The study objective was, to investigate whether the blood flow response to flicker stimulation is altered in patients with glaucoma.

NCT ID: NCT00788541 Terminated - Ocular Hypertension Clinical Trials

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00767494 Terminated - Glaucoma Clinical Trials

Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00767481 Terminated - Glaucoma Clinical Trials

1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT

Start date: October 2008
Phase: Phase 3
Study type: Interventional

Parallel, Multi-Center, Double-masked, Active controlled, three arm study comparing the IOP lowering efficacy and safety over 12 months of morning or evening instillations of Travoprost/Brinzolamide vs. Cosopt dosed in the morning and evening in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00758342 Terminated - Clinical trials for Intraocular Pressure

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Start date: May 2006
Phase: Phase 4
Study type: Interventional

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

NCT ID: NCT00644280 Terminated - Glaucoma Clinical Trials

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Start date: April 2008
Phase: N/A
Study type: Interventional

To determine whether ranibizumab therapy before and after tube insertion for glaucoma surgeries can maintain the patency of the tube and prevent scar formation, and increase the chances for a successful procedure compared to observation.

NCT ID: NCT00597181 Terminated - Glaucoma Clinical Trials

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

Optonol
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The less invasive nature of the Ex-Press Mini shunt with mitomycin C induces less post-operative inflammation than trabeculectomy with mitomycin c.

NCT ID: NCT00579969 Terminated - Glaucoma Clinical Trials

Comparison of Latanoprost Vs. Timolol

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to show, through a controlled masked clinical study of subjects with ocular hypertension (OHT), that latanoprost increases the low uveoscleral drainage of aqueous humor back to normal levels, and timolol maleate reduces the formation of aqueous humor below normal. Both of these mechanisms will effectively reduce intraocular pressure (IOP). The secondary purpose is to assess the effects of both latanoprost and timolol maleate on the fluorophotometric outflow facility, and episcleral venous pressure and on all parameters over time.